HIV/AIDS Topics HIV Treatment Conferences AASLD 2015
AASLD 2015: Sofosbuvir Plus Ribavirin Shows Suboptimal Efficacy for Acute Hepatitis C
- Details
- Category: Acute Hepatitis C
- Published on Thursday, 18 February 2016 00:00
- Written by Liz Highleyman
A combination of sofosbuvir (Sovaldi) and ribavirin cured more than 90% of HIV-positive people with acute hepatitis C virus (HCV) in a small study, but a similar trial of the same regimen saw a much higher relapse rate, according to a pair of presentations at the AASLD Liver Meeting this past November.
AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 12 February 2016 00:00
- Written by Liz Highleyman
A single injection of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log in people with HCV genotypes 1, 3, and 4, and 21% of treated patients still had undetectable virus levels 28 weeks after dosing, according to research presented at the AASLD Liver Meeting in November.
AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 December 2015 00:00
- Written by Liz Highleyman
Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C coinfection, was well-tolerated, and did not appear to interact with antiretrovirals, according to final results from the C-EDGE Co-infection study presented at the 2015 AASLD Liver Meeting last month in San Francisco. These results confirm that HIV/HCV coinfected people respond as well to interferon-free therapy as those with HCV alone.
AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 January 2016 00:00
- Written by Liz Highleyman
An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of non-cirrhotic hepatitis C patients with HCV genotypes 1, 2, or 3, according to late-breaking research presented at the AASLD Liver Meeting in November.
AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Hepatitis C patients who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir standard therapy, according to results from the SYNERGY study presented at the 2015 AASLD Liver Meeting last week in San Francisco. A related analysis showed that emergence of certain drug-resistance mutations was common during very short therapy, but this did not appear to compromise response to retreatment.
AASLD 2015: U.S. Faces Biggest Burden of Hepatitis C Treatment Costs Before 2020
- Details
- Category: HCV Treatment
- Published on Wednesday, 09 December 2015 00:00
- Written by Keith Alcorn
The cost of treating hepatitis C is likely to decline dramatically over the next decade in the U.S., not because of cuts in drug prices, but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the AASLD Liver Meeting in San Francisco last month.
AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Details
- Category: Fibrosis & Cirrhosis
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.
More Articles...
- AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks
- AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
- AASLD 2015: Study Reveals Potential Challenges for Scaling Up Hepatitis C Therapy in the UK
- AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
- AASLD 2015: Tenofovir During Pregnancy Reduces Risk of Mother-to-Child Hepatitis B Transmission
- AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
- AASLD 2015: Daclatasvir + Sofosbuvir Works Well for Genotype 3 HCV Patients with Advanced Disease
- AASLD 2015: Intensification with Sofosbuvir Permits Cure after Previous HCV Treatment Failure
- AASLD 2015: Liver Fibrosis Improves after Successful Treatment for Chronic Hepatitis C
- AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients
- AASLD 2015: New AbbVie Hepatitis C Combination Cures Up to 97% with Genotype 3
- AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C
- AASLD 2015: New AbbVie Pangenotypic Regimen Cures 97%-100% of Hepatitis C Patients in Early Study
- AASLD 2015: Sofosbuvir/ Velpatasvir Shows High Cure Rates for All HCV Genotypes in Phase 3
- AASLD 2015: People with Cirrhosis Cured of Hepatitis C Still Have Elevated Liver Cancer Risk
- AASLD 2015: Liver Doctors and Advocates Call for Wider Treatment of People with Hepatitis C
- AASLD 2015: Sofosbuvir/ Velpatasvir + GS-9857 for 8 Weeks Cures Most Genotype 1 or 3 Hepatitis C Patients
- AASLD 2015: HCV Infection During Anal Sex May Happen without Blood, Study Finds
- AASLD 2015: Grazoprevir/ Elbasvir Shows High Cure Rate for People Who Inject Drugs
- AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection
Web Design and Development by